Biogen (NASDAQ:BIIB) Sets New 12-Month High Following Analyst Upgrade

Key Points

• JPMorgan upgraded Biogen to “overweight” from “neutral” and raised its price target from $210 to $300, helping shares reach a new 52-week high.
• Analyst sentiment is broadly positive: Biogen has a consensus “Moderate Buy” rating and an average price target of $235.18, with UBS, Mizuho, and Canaccord Genuity also raising targets.
• Biogen reported quarterly earnings of $3.60 per share, exceeding estimates of $2.94, while revenue of $2.74 billion also surpassed expectations; institutional investors own approximately 87.93% of the stock.

Biogen Inc. (NASDAQ:BIIB - Get Free Report) shares reached a new 52-week high during trading on Monday after JPMorgan Chase & Co. upgraded the stock from a neutral rating to an overweight rating. JPMorgan Chase & Co. now has a $300.00 price target on the stock, up from their previous price target of $210.00. Biogen traded as high as $233.05 and last traded at $235.0730, with a volume of 20,833 shares trading hands. The stock had previously closed at $225.71.

Other equities analysts have also issued reports about the stock. UBS Group upped their target price on shares of Biogen from $240.00 to $270.00 and gave the stock a "buy" rating in a research note on Friday. Mizuho lifted their price target on Biogen from $221.00 to $241.00 and gave the company an "outperform" rating in a research note on Tuesday, August 4th. Bank of America cut their price target on Biogen from $217.00 to $215.00 and set a "neutral" rating on the stock in a report on Tuesday, July 21st. Zacks Research raised Biogen from a "strong sell" rating to a "hold" rating in a research report on Tuesday, July 28th. Finally, Canaccord Genuity Group boosted their target price on Biogen from $245.00 to $248.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $235.18.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: JPMorgan upgraded Biogen to “overweight” from “neutral” and raised its price target to $300 from $210. The new target implies approximately 32.9% upside from the referenced price, providing a significant bullish signal and likely driving investor interest. Biogen Raised to Overweight at JPMorgan Chase & Co.
• Positive Sentiment: JPMorgan said Biogen is positioned for gains from a slate of upcoming clinical-trial data releases, particularly potential 2027 pipeline catalysts. Investors appear to be assigning greater value to the company’s development portfolio beyond its current commercial products. Biogen is set for big gains on slate of trial data releases
• Neutral Sentiment: The analyst call comes as Wall Street begins repositioning ahead of third-quarter earnings season. While the broader research activity may increase attention on BIIB, the stock’s valuation and future performance will depend on execution and the success of forthcoming clinical programs. Monday’s Top Wall Street Analyst Research Calls

Institutional Investors Weigh In On Biogen

Large investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of Biogen in the second quarter worth $3,453,878,000. Primecap Management Co. CA acquired a new position in Biogen in the second quarter valued at about $3,274,304,000. Wellington Management Group LLP lifted its position in Biogen by 5.3% during the second quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company's stock worth $673,560,000 after purchasing an additional 155,828 shares during the period. Amundi lifted its position in Biogen by 91.8% during the second quarter. Amundi now owns 1,516,831 shares of the biotechnology company's stock worth $327,727,000 after purchasing an additional 726,004 shares during the period. Finally, Legal & General Group Plc acquired a new stake in Biogen during the second quarter worth about $322,640,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Biogen Price Performance

The stock has a market capitalization of $34.12 billion, a price-to-earnings ratio of 41.09, a P/E/G ratio of 2.49 and a beta of 0.09. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. The business's 50 day simple moving average is $217.41 and its 200-day simple moving average is $202.40.

Biogen (NASDAQ:BIIB - Get Free Report) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating the consensus estimate of $2.94 by $0.66. The firm had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business's quarterly revenue was up 3.4% compared to the same quarter last year. During the same period last year, the firm earned $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, research analysts forecast that Biogen Inc. will post 12.41 earnings per share for the current year.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen's products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich's ataxia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.